What is the difference between ARA-290 and Bronchogen?

ARA-290: ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair recep... Bronchogen: A short synthetic peptide bioregulator (Ala-Asp-Glu-Leu) from the Khavinson family, marketed for bronchial/respiratory tissue support. Evidence is largely Russian-language and preclinical....

ARA-290 vs Bronchogen

Q: Can you stack ARA-290 and Bronchogen?

ARA-290 (recovery) and Bronchogen (immune) are in different categories and are sometimes researched together in combined protocols. Consult a licensed provider before combining any compounds.

Head-to-head comparison of ARA-290 and Bronchogen — mechanism, dosing, side effects, legal status, and pricing.

ARA-290

ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.

Profile Prices Testing

Bronchogen

A short synthetic peptide bioregulator (Ala-Asp-Glu-Leu) from the Khavinson family, marketed for bronchial/respiratory tissue support. Evidence is largely Russian-language and preclinical.

Profile Prices Testing

ARA-290

Bronchogen

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

ARA-290

Best $/mg

$3.25/mg

Verified PeptidesC

11 trusted vendors listing

Compare all 11 vendors

Bronchogen

Best $/mg

$3.50/mg

BioLongevity LabsC

2 trusted vendors listing

Compare all 2 vendors

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

ARA-290

COAs

99.4%

Avg purity

Labs

Full testing data

Bronchogen

COAs

99.5%

Avg purity

Labs

Full testing data

ARA-290 Research Summary

Dahan et al. (Molecular Medicine, 2013, PMID 24136731) conducted a blinded placebo-controlled trial of 28 days of subcutaneous ARA 290 in sarcoidosis patients with documented small nerve fiber loss; treatment improved neuropathic symptoms, increased corneal nerve fiber density on confocal microscopy, altered thermal thresholds, and improved 6-minute walk distance. Brines et al. (Molecular Medicine, 2015, PMID 25387363) reported a placebo-controlled trial of 4 mg daily SubQ ARA 290 for 28 days in type 2 diabetes: the active arm showed improvements in HbA1c, lipid profile, and PainDetect neuropathic symptom scores, with recovery of intraepidermal nerve fiber measurements versus no change on placebo. Heij et al. (2012) and additional Phase 2 work have supported the tissue-protective signal. ARA-290 has not advanced to Phase 3 registration trials and is not FDA-approved.

Key references

Bronchogen Research Summary

Primarily Russian institutional studies; no large independent controlled human trials.

Can you stack ARA-290 and Bronchogen?

ARA-290 (Recovery) and Bronchogen (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.

Other comparisons

ARA-290 vs Thymosin Alpha-1 Bronchogen vs Thymosin Alpha-1 ARA-290 vs Thymulin Bronchogen vs Thymulin ARA-290 vs LL-37 Bronchogen vs LL-37 ARA-290 vs KPV Bronchogen vs KPV

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.